Nature Communications (Sep 2020)
Transcriptomic analysis links diverse hypothalamic cell types to fibroblast growth factor 1-induced sustained diabetes remission
- Marie A. Bentsen,
- Dylan M. Rausch,
- Zaman Mirzadeh,
- Kenjiro Muta,
- Jarrad M. Scarlett,
- Jenny M. Brown,
- Vicente Herranz-Pérez,
- Arian F. Baquero,
- Jonatan Thompson,
- Kimberly M. Alonge,
- Chelsea L. Faber,
- Karl J. Kaiyala,
- Camdin Bennett,
- Charles Pyke,
- Cecilia Ratner,
- Kristoffer L. Egerod,
- Birgitte Holst,
- Thomas H. Meek,
- Burak Kutlu,
- Yu Zhang,
- Thomas Sparso,
- Kevin L. Grove,
- Gregory J. Morton,
- Birgitte R. Kornum,
- José-Manuel García-Verdugo,
- Anna Secher,
- Rasmus Jorgensen,
- Michael W. Schwartz,
- Tune H. Pers
Affiliations
- Marie A. Bentsen
- UW Medicine Diabetes Institute, University of Washington
- Dylan M. Rausch
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- Zaman Mirzadeh
- Barrow Neurological Institute
- Kenjiro Muta
- UW Medicine Diabetes Institute, University of Washington
- Jarrad M. Scarlett
- UW Medicine Diabetes Institute, University of Washington
- Jenny M. Brown
- UW Medicine Diabetes Institute, University of Washington
- Vicente Herranz-Pérez
- Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia
- Arian F. Baquero
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Jonatan Thompson
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- Kimberly M. Alonge
- UW Medicine Diabetes Institute, University of Washington
- Chelsea L. Faber
- UW Medicine Diabetes Institute, University of Washington
- Karl J. Kaiyala
- Department of Oral Health Sciences, School of Dentistry, University of Washington
- Camdin Bennett
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Charles Pyke
- Pathology & Imaging, Global Discovery and Development Sciences, Novo Nordisk A/S
- Cecilia Ratner
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- Kristoffer L. Egerod
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- Birgitte Holst
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- Thomas H. Meek
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Burak Kutlu
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Yu Zhang
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Thomas Sparso
- Bioinformatics and Data Mining, Global Research Technologies, Novo Nordisk A/S
- Kevin L. Grove
- Obesity Research Unit, Novo Nordisk Research Center Seattle, Inc.
- Gregory J. Morton
- UW Medicine Diabetes Institute, University of Washington
- Birgitte R. Kornum
- Department of Neuroscience, University of Copenhagen
- José-Manuel García-Verdugo
- Cavanilles Institute of Biodiversity and Evolutionary Biology, University of Valencia
- Anna Secher
- Diabetes Research, Global Drug Discovery, Novo Nordisk A/S
- Rasmus Jorgensen
- Diabetes Research, Global Drug Discovery, Novo Nordisk A/S
- Michael W. Schwartz
- UW Medicine Diabetes Institute, University of Washington
- Tune H. Pers
- Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen
- DOI
- https://doi.org/10.1038/s41467-020-17720-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
In rodent models of type 2 diabetes, sustained remission of hyperglycemia can be induced by FGF1 action in the mediobasal hypothalamus. Here, the authors show that FGF1-injection is followed by marked changes in glial cell populations and that the sustained glycemic response is dependent on intact melanocortin signaling.
